BACKGROUND: Hepatitis C is a major cause of mortality among human immunodeficiency virus (HIV)-infected patients, yet hepatitis C virus (HCV) treatment uptake has historically been low. Although the removal of interferon removes a major barrier to HCV treatment uptake, oral therapies alone may not fully eliminate barriers in this population. METHODS: Within the Johns Hopkins Hospital HIV cohort, a nested case-control study was conducted to identify cases, defined as patients initiating HCV treatment between January 1996 and 2013, and controls, which were selected using incidence density sampling (3:1 ratio). Controls were matched to cases on date of enrollment. Conditional logistic regression was used to evaluate factors associated with HCV treatment initiation. RESULTS: Among 208 treated cases and 624 untreated controls, the presence of advanced fibrosis (odds ratio [OR], 2.23; 95% confidence interval [CI], 1.26-3.95), recent active drug use (OR, 0.36; 95% CI, 0.19-0.69), and non-black race (OR, 2.01; 95% CI, 1.26-3.20) were independently associated with initiation of HCV therapy. An increasing proportion of missed visits was also independently associated with lower odds of HCV treatment (25%-49% missed visits [OR, 0.49; 95% CI, 0.27-0.91] and ≥50% missed visits [OR, 0.24; 95% CI, 0.12-0.48]). CONCLUSIONS: Interferon-free treatments may not be sufficient to fully overcome barriers to HCV care in HIV-infected patients. Interventions to increase engagement in care for HIV and substance use are needed to expand HCV treatment uptake. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Hepatitis C is a major cause of mortality among human immunodeficiency virus (HIV)-infectedpatients, yet hepatitis C virus (HCV) treatment uptake has historically been low. Although the removal of interferon removes a major barrier to HCV treatment uptake, oral therapies alone may not fully eliminate barriers in this population. METHODS: Within the Johns Hopkins Hospital HIV cohort, a nested case-control study was conducted to identify cases, defined as patients initiating HCV treatment between January 1996 and 2013, and controls, which were selected using incidence density sampling (3:1 ratio). Controls were matched to cases on date of enrollment. Conditional logistic regression was used to evaluate factors associated with HCV treatment initiation. RESULTS: Among 208 treated cases and 624 untreated controls, the presence of advanced fibrosis (odds ratio [OR], 2.23; 95% confidence interval [CI], 1.26-3.95), recent active drug use (OR, 0.36; 95% CI, 0.19-0.69), and non-black race (OR, 2.01; 95% CI, 1.26-3.20) were independently associated with initiation of HCV therapy. An increasing proportion of missed visits was also independently associated with lower odds of HCV treatment (25%-49% missed visits [OR, 0.49; 95% CI, 0.27-0.91] and ≥50% missed visits [OR, 0.24; 95% CI, 0.12-0.48]). CONCLUSIONS: Interferon-free treatments may not be sufficient to fully overcome barriers to HCV care in HIV-infectedpatients. Interventions to increase engagement in care for HIV and substance use are needed to expand HCV treatment uptake. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Anu Osinusi; Kerry Townsend; Anita Kohli; Amy Nelson; Cassie Seamon; Eric G Meissner; Dimitra Bon; Rachel Silk; Chloe Gross; Angie Price; Mohammad Sajadi; Sreetha Sidharthan; Zayani Sims; Eva Herrmann; John Hogan; Gebeyehu Teferi; Rohit Talwani; Michael Proschan; Veronica Jenkins; David E Kleiner; Brad J Wood; G Mani Subramanian; Phillip S Pang; John G McHutchison; Michael A Polis; Anthony S Fauci; Henry Masur; Shyam Kottilil Journal: JAMA Date: 2015 Mar 24-31 Impact factor: 56.272
Authors: Mark S Sulkowski; Joseph J Eron; David Wyles; Roger Trinh; Jay Lalezari; Chia Wang; Jihad Slim; Laveeza Bhatti; Joseph Gathe; Peter J Ruane; Richard Elion; Fritz Bredeek; Robert Brennan; Gary Blick; Amit Khatri; Krystal Gibbons; Yiran B Hu; Linda Fredrick; Gretja Schnell; Tami Pilot-Matias; Rakesh Tripathi; Barbara Da Silva-Tillmann; Barbara McGovern; Andrew L Campbell; Thomas Podsadecki Journal: JAMA Date: 2015 Mar 24-31 Impact factor: 56.272
Authors: Susanna Naggie; Curtis Cooper; Michael Saag; Kimberly Workowski; Peter Ruane; William J Towner; Kristen Marks; Anne Luetkemeyer; Rachel P Baden; Paul E Sax; Edward Gane; Jorge Santana-Bagur; Luisa M Stamm; Jenny C Yang; Polina German; Hadas Dvory-Sobol; Liyun Ni; Phillip S Pang; John G McHutchison; Catherine A M Stedman; Javier O Morales-Ramirez; Norbert Bräu; Dushyantha Jayaweera; Amy E Colson; Pablo Tebas; David K Wong; Douglas Dieterich; Mark Sulkowski Journal: N Engl J Med Date: 2015-07-21 Impact factor: 91.245
Authors: Gregory D Kirk; Shruti H Mehta; Jacquie Astemborski; Noya Galai; Jonathan Washington; Yvonne Higgins; Ashwin Balagopal; David L Thomas Journal: Ann Intern Med Date: 2013-05-07 Impact factor: 25.391
Authors: Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245
Authors: Jennifer O Lam; Leo B Hurley; Scott Chamberland; Jamila H Champsi; Laura C Gittleman; Daniel G Korn; Jennifer B Lai; Charles P Quesenberry; Joanna Ready; Varun Saxena; Suk I Seo; David J Witt; Michael J Silverberg; Julia L Marcus Journal: Int J STD AIDS Date: 2019-05-02 Impact factor: 1.359
Authors: Tessa M Nápoles; Abigail W Batchelder; Ada Lin; Lissa Moran; Mallory O Johnson; Martha Shumway; Anne F Luetkemeyer; Marion G Peters; Kellene V Eagen; Elise D Riley Journal: J Public Health (Oxf) Date: 2019-12-20 Impact factor: 2.341
Authors: Eshan U Patel; Sunil S Solomon; Allison M Mcfall; Aylur K Srikrishnan; Amrose Pradeep; Paneerselvam Nandagopal; Oliver Laeyendecker; Aaron A R Tobian; David L Thomas; Mark S Sulkowski; M Suresh Kumar; Shruti H Mehta Journal: Int J Drug Policy Date: 2018-04-19
Authors: Daniel Radwan; Edward Cachay; Oluwaseun Falade-Nwulia; Richard D Moore; Ryan Westergaard; William Christopher Mathews; Judith Aberg; Laura Cheever; Kelly A Gebo Journal: J Acquir Immune Defic Syndr Date: 2019-04-15 Impact factor: 3.731
Authors: Meredith E Clement; Lauren F Collins; Julius M Wilder; Michael Mugavero; Taryn Barker; Susanna Naggie Journal: Infect Dis Clin North Am Date: 2018-06 Impact factor: 5.982
Authors: Kathleen M Ward; Sean D McCormick; Mark Sulkowski; Carl Latkin; Geetanjali Chander; Oluwaseun Falade-Nwulia Journal: Int J Drug Policy Date: 2020-11-04
Authors: Lauren F Collins; Austin Chan; Jiayin Zheng; Shein-Chung Chow; Julius M Wilder; Andrew J Muir; Susanna Naggie Journal: Open Forum Infect Dis Date: 2017-12-09 Impact factor: 3.835
Authors: Lindsy Liu; Monika N Daftary; Mohammad S Alzahrani; Chiemena Ohanele; Mary K Maneno Journal: J Natl Med Assoc Date: 2020-08-28 Impact factor: 1.798